Mutational Status Of Advanced Lung Adenocarcinoma In A Portuguese Cohort

Background: Lung cancer treatment paradigm has changed progressively based on tumor biomarkers. Next-generation sequencing (NGS) detects several mutations in oncogenic drivers, thus predicting the response to targeted therapies. This study aimed to understand the impact of mutational status in advanced lung adenocarcinoma (ADC) presentation and prognosis. Methods: A retrospective analysis of detected mutations and their clinical correlations was performed in patients with stage III-IV lung ADC, who performed a molecular study with NGS. Results: A total of 127 patients were studied (mean age 67.6±10.8 years, 63% male, 33.9% non-smokers, 82.6% stage IV). An oncogenic mutation was present in 63.1% of patients, most commonly KRAS mutation (27.6%), followed by EGFR mutation (14.2%) and ALK rearrangement (6.3%). KRAS mutation was mostly found in males (80%) and ex-smokers (48.6%), while EGFR mutation in females (77.8%) and non-smokers (61.1%), with p Conclusions: Molecular characterization plays a key role in stratifying patients that will benefit from targeted therapy, but also provides prognostic information that could support future clinical strategies for lung ADC patients.